Two new competitive immunoenzymatic assays (“C.I.C.-conglutinin” and “C.I.C.-C1q“) were employed to evaluate circulating immunocomplexes in 90 patients with a variety of autoimmune and neoplastic disorders. In autoimmune diseases the assays appeared very sensitive and relatively concordant, while in malignancies sensitivity was high with the C.I.C.-conglutinin method but much lower with the C.I.C.-C1q method. The clinical significance of these results is discussed with particular regard to the possibilities of application of the two assays in the diagnostic routine of a general hospital laboratory.
GnemmiE., MiglioriniP., CheregattiG., MancaF., CantarellaS., CeladaF.A new competitive immunoenzymatic assay to determine circulating immunocomplexes.9th Int. Symposium on Clinical Enzymology, Verona (Italy), 1980.
2.
MancaF., MiglioriniP., BombardieriS., CeladaF.An en-zymatically active antigen-antibody probe to measure circulating immune complexes by competition.J Clin Immunol and Immunopathol1980; 16: 131–41.
3.
LurhumaA., CambiasoC., MassonP., HeremansJ.Detection of circulating antigen-antibody complexes by their inhibitory effect on the agglutination of IgG-coated particles by rheumatoid factor or C1q.Clin Exp Immunol1976; 25: 212–26.
4.
RossenR., ZublerR., DayN., HershE.Detection of im-munocomplex-like materials in cancer patients’ sera: a comparative study of results obtained with the C1q deviation and C1q binding tests.J Lab Clin Med1978; 91: 191–204.
5.
HussonJ., DruetP., ContetA., CamilleriJ.Systemic sclerosis and cryoglobulinemia.Clin Immunol and Immunopathol1976; 6: 77–82.
